Page 4 - Eric Schoen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cassava Sciences (SAVA) Reports Q3 EPS of ($0 61), Provides Update

Cassava Sciences (SAVA) Reports Q3 EPS of ($0 61), Provides Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesEric schoenRemi barbierCassava sciences incCassava sciencesCassava scienceSafety monitoring boardThird quarterMore information contactChief financialNote regarding forward looking statementsPrivate securities litigation reform actAnnual reportFinancial tables follow

Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results

07.11.2023 - Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer s.Over 1,900 patients randomized in on-going Phase 3 trials.Top-line results for 52-week Phase 3 trial expected approximately year-end 2024; top-line results for 76-week .

United statesRemi barbierEric schoenCassava sciencesCassava sciences incCassava scienceSafety monitoring boardThird quarterMore information contactChief financialNote regarding forward looking statementsPrivate securities litigation reform actAnnual reportFinancial tables follow

Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer s Disease -November 06, 2023 at 09:16 am EST

1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer s disease dementia.Top-line results for on-going, 52-week Phase 3 trial expected approximately year-end.

South koreaUnited statesPuerto ricoRemi barbierEric schoenCassava sciences incCassava sciencesResearch internationalCassava scienceSpecial protocol assessmentPremier research internationalSafety monitoring boardMore information contactChief financialNote regarding forward looking statementsPrivate securities litigation reform act

MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)

MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesEric schoenSuzanne hendrixPentara corporationCassava sciences incCassava sciencesSafety finding basedKnown risk factorAnti amyloid antibodyCassava scienceClinical trialsWithdrawal studyMild to moderate alzheimerPrimary mechanismFaction confirmedMore information contact

MRI Data Suggest Simufilam is Not Associated with

Safety Finding Based on Blinded MRI Brain Data at Week 40ARIA is a Known Risk Factor for Anti-Amyloid Antibody DrugsMRI Data Presented at the 16th CTAD.

United statesSuzanne hendrixEric schoenCassava sciencesCassava sciences incPentara corporationSafety finding basedKnown risk factorAnti amyloid antibodyCassava scienceClinical trialsWithdrawal studyMild to moderate alzheimerPrimary mechanismFaction confirmedMore information contact